Claims
- 1. The method for inhibiting the immediate hypersensitivity reaction in a mammal sensitive to allergic reaction which comprises administering to said mammal a non-toxic effective hypersensitive reaction inhibiting dose of a compound selected from the group consisting of those having the following formula and the pharmaceutically acceptable acid addition salts thereof ##STR26## wherein R.sup.6, R.sup.7, R.sup.11 and R.sup.12 are selected from the group consisting of hydrogen and methyl.
- 2. The method of claim 1 wherein said compound is 4-[(4-chlorophenyl)methyl]-6,7-dihydro-3H-imidazo[1,2-a]purin-9(4H)one.
- 3. The method of claim 1 wherein said compound is 4-[(4-chlorophenyl)methyl]-6,7-dihydro-3H-imidazo[1,2-a]purin-9(4H)-one hydrochloride.
- 4. The method of claim 1 wherein said compound is 4-[(4-chlorophenyl)methyl]-6,7-dihydro-2-methyl-3H-imidazo[1,2-a]purin-9(4H)-one.
- 5. The method of claim 1 wherein said compound is 4-[(4-chlorophenyl)methyl]-6,7-dihydro-6-methyl-3H-imidazo[1,2-a]purin-9(4H)-one.
- 6. The method of claim 1 wherein said compound is 4-[(4-chlorophenyl)methyl]-6,7-dihydro-2,6-dimethyl-3H-imidazo[1,2-a]purin-9(4H)-one.
- 7. The method of claim 1 wherein said compound is 4-[(4-chlorophenyl)methyl]-6,7-dihydro-1,6-dimethyl-1H-imidazo[1,2-a]purin-9(4H)-one.
- 8. The method of claim 1 wherein said compound is 4-[(4-chlorophenyl)methyl]-6,7-dihydro-1,2,6-trimethyl-1H-imidazo[1,2-a]purin-9(4H)-one.
- 9. The method of claim 1 wherein said compound is selected from the group consisting of 4-[(4-chlorophenyl)methyl]-6,7-dihydro-6,6-dimethyl-3H-imidazo[1,2-a]purin-9(4H)-one and a pharmaceutically acceptable acid addition salt thereof.
- 10. The method of claim 1 wherein said compound is 4-[(4-chlorophenyl)methyl]-6,7-dihydro-6,6-dimethyl-3H-imidazo[1,2-a]purin-9(4H)-one.
- 11. The method of claim 1 wherein said compound is 4-[(4-chlorophenyl)methyl]-6,7-dihydro-6,7-dimethyl-3H-imidazo[1,2-a]purin-9(4H)-one.
- 12. The method of claim 1 wherein said compound is 4-[(4-chlorophenyl)methyl]-6,7-dihydro-trans-6,7-dimethyl-3H-imidazo[1,2-a]purin-9(4H)-one.
- 13. The method of claim 1 wherein said compound is 4-[(4-chlorophenyl)methyl]-6,7-dihydro-cis-6,7-dimethyl-3H-imidazo[1,2-a]purin-9(4H)-one.
- 14. The method for inhibiting the immediate hypersensitivity reaction in a mammal sensitive to allergic reaction which comprises administering to said mammal a non-toxic effective hypersensitive reaction inhibiting dose of a compound selected from the group consisting of those having the following formula and the pharmaceutically acceptable acid addition salts thereof ##STR27## wherein R.sup.12 is lower alkyl.
- 15. The method of claim 14 wherein said compound is 6,7-dihydro-2-methyl-4-(2-phenoxyethyl)imidazo[1,2-a]purin-9(4H)-one.
- 16. The method of claim 14, wherein said compound is 6,7-dihydro-2-(1-methylethyl)-4-(2-phenoxyethyl)-3H-imidazo[1,2-a]purin-9(4H)-one.
- 17. The method for inhibiting the immediate hypersensitivity reaction in a mammal sensitive to allergic reaction which comprises administering to said mammal a non-toxic effective hypersensitive reaction inhibiting dose of a compound selected from the group consisting of those having the following formula and the pharmaceutically acceptable acid addition salts thereof ##STR28## wherein R.sup.12 is lower alkyl.
- 18. The method of claim 17 wherein said compound is 6,7-dihydro-2-(1-methylethyl)-4-(2-methylpropyl)-3H-imidazo[1,2-a]purin-9(4H)-one.
- 19. The method of claim 17 wherein said compound is 6,7-dihydro-2-methyl-4-(2-methylpropyl)3H-imidazo[1,2-a]purin-9(4H)-one.
- 20. The method for inhibiting the immediate hypersensitivity reaction in a mammal sensitive to allergic reaction which comprises administering to said mammal a non-toxic effective hypersensitive reaction inhibiting dose of a compound selected from the group consisting of
- (a) 4-[(3-chlorophenyl)methyl]-6,7-dihydro-3H-imidazo[1,2-a]purin-9(4H)-one;
- (b) 4-[(2-chlorophenyl)methyl]-6,7-dihydro-3H-imidazo[1,2-a]purin-9(4H)-one;
- (c) 4-[(4-fluorophenyl)methyl]-6,7-dihydro-3H-imidazo[1,2-a]purin-9(4H)-one;
- (d) 4-(2-pyridylmethyl)-6,7-dihydro-3H-imidazo[1,2-a]purin-9(4H)-one;
- (e) 4-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dihyro-3H-imidazo[1,2-a]purin-9(4H)-one;
- (f) 6,7-dihydro-4-(2-phenoxyethyl)-3H-imidazo[1,2-a]purin-9(4H)-one;
- (g) 4-[(4-chlorophenyl)methyl]-2-ethyl-6,7-dihydroimidazo[1,2-a]purin-9(4H)-one;
- (h) 2-bromo-4-[(4-chlorophenyl)methyl]-6,7-dihydro-3H-imidazo[1,2-a]purin-9(4H)-one;
- (i) 6,7-dihydro-2-(1-methylethyl)-4-(2-methylpropionyl)-3H-imidazo[1,2-a]purin-9(4H)-one;
- (j) 6,7-dihydro-2-methyl-4-octyl-3H-imidazo[1,2-a]purin-9(4H)-one;
- (k) 6,7-dihydro-2-(1-methylethyl)-4-octylimidazo[1,2-a]purin-9(4H)-one;
- (l) 4-[2-(4-chlorophenoxy)ethyl]-6,7-dihydro-3H-imidazo[1,2-a]purin-9(4H)-one;
- (m) 4-(cyclohexylmethyl)-6,7-dihydro-3H-imidazo[1,2-a]purin-9(4H)-one; and
- (n) 4-[(4-chlorophenyl)methyl]-6,7-dihydro-1-methyl-1H-imidazo[1,2-a]purin-9(4H)-one.
REFERENCE TO RELATED APPLICATION
This application is a divisional of co-pending application Ser. No. 017,771 filed Mar. 5, 1979 and now U.S. Pat. No. 4,298,734, issued Nov. 3, 1981 which is a continuation-in-part of application Ser. No. 869,203 filed Jan. 13, 1978 and abandoned Mar. 17, 1979, which in turn is a continuation-in-part of application Ser. No. 768,291 filed Feb. 14, 1977 and abandoned Oct. 13, 1978.
Divisions (1)
|
Number |
Date |
Country |
Parent |
17771 |
Mar 1979 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
869203 |
Jan 1978 |
|
Parent |
768291 |
Feb 1977 |
|